Company profile for FibroBiologics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

FibroBiologics is a pioneering biopharmaceutical company specializing in the development and distribution of fibroblast cell-based therapies for patients with chronic illnesses. Our exclusive fibroblast platform forms the basis for creating biological cures and remedies for various chronic conditions, spanning from degenerative disc disease and multiple sclerosis to wound healing and cancer. Additionally, we explore applicatio...
FibroBiologics is a pioneering biopharmaceutical company specializing in the development and distribution of fibroblast cell-based therapies for patients with chronic illnesses. Our exclusive fibroblast platform forms the basis for creating biological cures and remedies for various chronic conditions, spanning from degenerative disc disease and multiple sclerosis to wound healing and cancer. Additionally, we explore applications for extending life and reversing age-related declines, such as thymic involution and splenic involution.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Houston, TX 77598
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/10/3203156/0/en/FibroBiologics-Files-Patent-Application-Covering-Novel-Fibroblast-Based-Chondrocyte-Spheroid-Platform-for-Orthopedic-and-Musculoskeletal-Conditions.html

GLOBENEWSWIRE
10 Dec 2025

https://www.globenewswire.com/news-release/2025/11/26/3195134/0/en/FibroBiologics-Announces-Payoff-of-Outstanding-Debt.html

GLOBENEWSWIRE
26 Nov 2025

https://www.globenewswire.com/news-release/2025/11/25/3194723/0/en/FibroBiologics-Announces-Closing-of-1-5-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html

GLOBENEWSWIRE
25 Nov 2025

https://www.globenewswire.com/news-release/2025/11/24/3193572/0/en/FibroBiologics-Announces-1-5-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html

GLOBENEWSWIRE
24 Nov 2025

https://www.globenewswire.com/news-release/2025/11/20/3191847/0/en/FibroBiologics-Receives-HREC-Approval-for-Phase-1-2-Clinical-Trial-for-CYWC628-for-the-Treatment-of-Refractory-Diabetic-Foot-Ulcers.html

GLOBENEWSWIRE
20 Nov 2025

https://www.globenewswire.com/news-release/2025/11/20/3191538/0/en/FibroBiologics-Announces-Closing-of-4-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html

GLOBENEWSWIRE
19 Nov 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty